Welcome to our dedicated page for BioScience Health Innovations SEC filings (Ticker: BHIC), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Our SEC filing database is enhanced with expert analysis from Rhea-AI, providing insights into the potential impact of each filing on BioScience Health Innovations's stock performance. Each filing includes a concise AI-generated summary, sentiment and impact scores, and end-of-day stock performance data showing the actual market reaction. Navigate easily through different filing types including 10-K annual reports, 10-Q quarterly reports, 8-K current reports, proxy statements (DEF 14A), and Form 4 insider trading disclosures.
Designed for fundamental investors and regulatory compliance professionals, our page simplifies access to critical SEC filings. By combining real-time EDGAR feed updates, Rhea-AI's analytical insights, and historical stock performance data, we provide comprehensive visibility into BioScience Health Innovations's regulatory disclosures and financial reporting.
BioScience Health Innovations (BHIC) filed its quarterly report for the period ended September 30, 2025. The company posted strong year-to-date results, with revenue of $4,115,960 and net income of $875,720, compared with $1,234,744 and $77,043 a year earlier. In Q3, revenue was $1,131,427 and the company recorded a small net loss of $8,782 as operating expenses rose with growth.
Cash was $1,139,423, inventory increased to $757,500, and total assets reached $2,067,100. Current liabilities were $356,140, including $228,298 due to related parties. Operating cash flow was positive at $272,874. The company expanded authorized common stock to 250,000,000 and executed a 1‑for‑4 reverse split; 10,979,055 common shares were outstanding as of October 24, 2025. There are 140,000 Series A preferred shares outstanding, each convertible into three common shares subject to a 4.99% beneficial ownership limit.
Management disclosed material weaknesses in internal controls and noted substantial doubt about the company’s ability to continue as a going concern due to historical losses and reliance on related-party advances, despite improved year-to-date profitability.
BioScience Health Innovations, Inc. effected a reverse stock split, consolidating every 4 shares of common stock into 1 share, effective September 10, 2025. The Board approved the action under Nevada law, and a majority of shares entitled to vote approved it by written consent.
The company states the reverse split does not affect stockholder rights, and no other amendments were made to the certificate of incorporation. A certificate of amendment was filed with the Nevada Secretary of State.